Lapatinib Ditosylate in Treating Patients With Ductal Breast Carcinoma In Situ

Summary

This randomized phase I/II trial studies the side effects and best dose of lapatinib ditosylate and to see how well it works in treating patients with ductal breast carcinoma in situ. Lapatinib ditosylate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.

Timeline

Start

2009-08-19

Primary completion

2014-08-28

Completion

2014-08-28

Drugs

Indications